Avian Influenza Virus Type A H9N2 subtype NP antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Avian Influenza Virus Type A H9N2 subtype NP antibodies pairs and antigen for animal health (animal Avian/Bird/Poultry infectious disease Avian influenza) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Avian/Bird/Poultry disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P215-Tg003-Ag01	Recombinant Avian Influenza Virus Type A H9N2 subtype NP protein	$3090.00
GMP-VT-P215-Tg003-Ab01	Anti-Avian Influenza Virus Type A H9N2 subtype NP mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P215-Tg003-Ab02	Anti-Avian Influenza Virus Type A H9N2 subtype NP mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P215-Tg003-Ab03	Anti-Avian Influenza Virus Type A H9N2 subtype NP human monoclonal antibody (mAb)	$3090.00
GMP-VT-P215-Tg003-Ab04	Anti-Avian Influenza Virus Type A H9N2 subtype NP human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P215-Tg003-Ag01
Product Name	Recombinant Avian Influenza Virus Type A H9N2 subtype NP protein
Pathogen	Avian Influenza Virus Type A H9N2 subtype
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Avian Influenza Virus Type A H9N2 subtype NP antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Avian Influenza Virus Type A H9N2 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza.
Tag	His
Product description	Recombinant Avian Influenza Virus Type A H9N2 subtype NP proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P215-Tg003-Ab01,GMP-VT-P215-Tg003-Ab02
Pathogen	Avian Influenza Virus Type A H9N2 subtype
Product Name	Anti-Avian Influenza Virus Type A H9N2 subtype NP mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Avian Influenza Virus Type A H9N2 subtype NP antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A H9N2 subtype antibodies in Avian Influenza Virus Type A H9N2 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza.
Product description	Anti-Avian Influenza Virus Type A H9N2 subtype NP mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A H9N2 subtype antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P215-Tg003-Ab03,GMP-VT-P215-Tg003-Ab04
Pathogen	Avian Influenza Virus Type A H9N2 subtype
Product Name	Anti-Avian Influenza Virus Type A H9N2 subtype NP human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Avian Influenza Virus Type A H9N2 subtype NP antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Avian Influenza Virus Type A H9N2 subtype antibodies in Avian Influenza Virus Type A H9N2 subtype level test of animal Avian/Bird/Poultry infectious disease with Avian influenza.
Product description	Anti-Avian Influenza Virus Type A H9N2 subtype NP mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

H9N2 avian influenza virus is an orthomyxovirus that belongs to the family Orthomyxoviridae. The virus has a spherical shape and is enveloped, with a segmented genome consisting of eight RNA segments that encode for the different viral proteins. The viral proteins include polymerase basic protein 2 (PB2), polymerase basic protein 1 (PB1), polymerase acidic protein (PA), hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA), and matrix protein (M). These proteins are critical for the replication and transmission of the virus, as well as its pathogenicity.

H9N2 avian influenza virus primarily infects birds, such as domestic poultry, but it can also infect humans and other mammals, including pigs and dogs. In birds, H9N2 infection can cause respiratory distress, decreased egg production, and even death. However, the virus can be asymptomatic in some bird species, making it challenging to detect and control. In humans, H9N2 infection usually results in mild upper respiratory symptoms, such as fever, cough, and sore throat. However, in rare cases, the virus can lead to severe respiratory complications, such as pneumonia.

The transmission of H9N2 avian influenza virus occurs mainly through contact with infected birds or their secretions, such as feces, nasal secretions, and saliva. The virus can also be transmitted through contaminated surfaces and objects. Human-to-human transmission of H9N2 avian influenza virus is rare and limited to close contact with infected individuals. However, the virus's ability to infect humans and other mammals raises concerns about the potential for viral reassortment and the emergence of novel influenza viruses with pandemic potential.

The diagnosis of H9N2 avian influenza virus can be challenging, as the symptoms in birds are non-specific, and the virus can remain asymptomatic in some bird species. The most common diagnostic tests for H9N2 avian influenza virus include nucleic acid-based tests, such as RT-PCR and qRT-PCR, which target the virus's specific gene segments. These tests can detect the virus in various clinical samples, such as nasal swabs, feces, and blood. Serological tests, such as ELISA, can also be used to detect antibodies against the virus in suspected cases of infection.

The prevention and control of H9N2 avian influenza virus depend on implementing effective biosecurity measures, such as strict sanitation practices, quarantining of infected birds, and culling infected flocks. Additionally, vaccination programs in poultry populations can reduce the spread of the virus and limit its transmission to humans. In humans, antiviral medications, such as neuraminidase inhibitors, can be effective in treating H9N2 avian influenza virus infections, but their effectiveness is dependent on early diagnosis and prompt treatment.

In conclusion, H9N2 avian influenza virus is an important zoonotic pathogen that infects birds, humans, and other mammals. The virus's ability to infect multiple species and the risk of viral reassortment underscore the importance of effective surveillance and control measures to prevent the emergence of novel influenza viruses with pandemic potential.

About GDU